When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.
about
Why a universal antiretroviral regimen?Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study
P2860
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
When could new antiretrovirals ...... : results of a WHO Think Tank.
@ast
When could new antiretrovirals ...... : results of a WHO Think Tank.
@en
type
label
When could new antiretrovirals ...... : results of a WHO Think Tank.
@ast
When could new antiretrovirals ...... : results of a WHO Think Tank.
@en
prefLabel
When could new antiretrovirals ...... : results of a WHO Think Tank.
@ast
When could new antiretrovirals ...... : results of a WHO Think Tank.
@en
P2093
P2860
P921
P1476
When could new antiretrovirals ...... : results of a WHO Think Tank.
@en
P2093
Andrew M Hill
Anton L Pozniak
Marco Vitoria
Nathan Ford
Polly Clayden
P2860
P304
P356
10.1097/COH.0000000000000380
P577
2017-04-12T00:00:00Z
2017-07-01T00:00:00Z